Skip to main content
. 2019 Nov 19;98(1):54–66. doi: 10.1111/imcb.12297

Figure 7.

Figure 7

5′ AMP‐activated protein kinase (AMPK) activator (AICAR) treatment alleviates thioacetamide (TAA)‐induced acute liver injury in hyperglycemic mice. (a–c) Serum levels of aspartate transaminase (sAST) and alanine aminotransferase (sALT; n = 6 mice/group) and liver histopathology (representative of six experiments) were used to evaluate liver injury in diabetic mice and controls post‐AICAR and TAA treatment. (d) Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining of liver sections (200× magnification, representative of six experiments). (e) The relative ratio of TUNEL‐positive cells in different groups (n = 6 mice/group). (f) The levels of Bcl‐2, Bcl‐xL and β‐actin proteins were measured by western blot (representative of three experiments). *P < 0.05. AICAR, 5‐aminoimidazole‐4‐carboxamide ribonucleotide; CON, control; NLRP3, NOD‐like receptor family pyrin domain‐containing 3 protein; STZ, streptozotocin.